Nagahiro Minato Selected Research

GTPase-Activating Proteins (GTPase-Activating Protein)

12/2020	SIPA1 enhances SMAD2/3 expression to maintain stem cell features in breast cancer cells.
1/2018	Sipa1 deficiency-induced bone marrow niche alterations lead to the initiation of myeloproliferative neoplasm.
4/2011	Increased c-Myc activity and DNA damage in hematopoietic progenitors precede myeloproliferative disease in Spa-1-deficiency.
4/2011	SPA-1 controls the invasion and metastasis of human prostate cancer.
1/2009	Spa-1 (Sipa1) and Rap signaling in leukemia and cancer metastasis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nagahiro Minato Research Topics

Disease

33	Neoplasms (Cancer) 06/2021 - 09/2002
8	Breast Neoplasms (Breast Cancer) 06/2021 - 04/2011
6	Neoplasm Metastasis (Metastasis) 12/2020 - 06/2004
5	Inflammation (Inflammations) 01/2019 - 01/2016
4	Renal Cell Carcinoma (Grawitz Tumor) 08/2011 - 04/2007
3	Carcinoma (Carcinomatosis) 05/2013 - 09/2003
3	Leukemia 09/2009 - 04/2006
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2018 - 10/2006
2	Multiple Myeloma 01/2017 - 04/2013
2	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2015 - 03/2008
2	Nephritis 03/2010 - 04/2006
1	Virus Diseases (Viral Diseases) 12/2020
1	Hypotension (Low Blood Pressure) 01/2018
1	Juvenile Myelomonocytic Leukemia 01/2018
1	Sepsis (Septicemia) 01/2018
1	Hemolytic Anemia 12/2017
1	Anemia 12/2017
1	Bone Resorption 01/2017
1	Fibrosarcoma 01/2017
1	Urinary Bladder Neoplasms (Bladder Cancer) 01/2017
1	Hepatitis C 01/2017
1	Circulating Neoplastic Cells 10/2016
1	Skin Neoplasms (Skin Cancer) 04/2016
1	Lupus Nephritis 06/2015
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2015
1	Infections 01/2014
1	Lymphoma (Lymphomas) 05/2013
1	Myeloid Leukemia (Leukemia, Myelocytic) 05/2013
1	Hyperplasia 01/2012
1	Hydronephrosis 01/2012
1	Lymphatic Metastasis 04/2011
1	Myeloproliferative Disorders (Myeloproliferative Disorder) 04/2011
1	Blast Crisis (Blast Phase) 04/2011
1	Night Blindness (Nyctalopia) 06/2009
1	Fatigue 04/2007
1	Fever (Fevers) 04/2007
1	Colorectal Neoplasms (Colorectal Cancer) 04/2007

Drug/Important Bio-Agent (IBA)

8	Zoledronic Acid (Zometa)FDA Link 04/2018 - 02/2010
7	LigandsIBA 01/2016 - 06/2004
5	GTPase-Activating Proteins (GTPase-Activating Protein)IBA 12/2020 - 01/2009
5	Diphosphonates (Bisphosphonates)IBA 04/2018 - 04/2003
4	T-Cell Antigen Receptors (T-Cell Receptor)IBA 03/2018 - 09/2002
3	Proteins (Proteins, Gene)FDA Link 06/2021 - 12/2003
3	AntigensIBA 12/2020 - 07/2006
3	CytokinesIBA 01/2018 - 02/2011
3	NitrogenIBA 12/2016 - 04/2003
3	AntibodiesIBA 01/2016 - 09/2003
2	Biomarkers (Surrogate Marker)IBA 12/2019 - 10/2016
2	OsteopontinIBA 01/2019 - 06/2015
2	Letrozole (Femara)FDA LinkGeneric 04/2018 - 11/2014
2	Estrogen ReceptorsIBA 04/2018 - 11/2014
2	InterferonsIBA 03/2018 - 01/2017
2	ProdrugsIBA 01/2017 - 12/2016
2	ChemokinesIBA 01/2016 - 06/2004
2	Interleukin-2 (IL2)IBA 08/2011 - 02/2010
2	GTP Phosphohydrolases (GTPases)IBA 01/2009 - 10/2003
2	AutoantibodiesIBA 04/2006 - 12/2003
1	Epirubicin (Ellence)FDA LinkGeneric 06/2021
1	Pharmaceutical PreparationsIBA 06/2021
1	Nuclear Proteins (Protein, Nuclear)IBA 06/2021
1	ErbB Receptors (EGF Receptor)IBA 04/2018
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2018
1	Bile Acids and Salts (Bile Acids)IBA 01/2018
1	Taurodeoxycholic AcidIBA 01/2018
1	bcr-abl Fusion ProteinsIBA 01/2018
1	Antigen-Antibody Complex (Immune Complex)IBA 01/2018
1	ProteomeIBA 01/2018
1	phenylhydrazine (phenylhydrazine hydrochloride)IBA 12/2017
1	Erythropoietin FDA Link 12/2017
1	EstersIBA 01/2017
1	Organophosphonates (Phosphonates)IBA 01/2017
1	AcidsIBA 01/2017
1	Phosphates (Orthophosphate)IBA 01/2017
1	NucleotidesIBA 01/2017
1	EsterasesIBA 12/2016
1	Tumor Biomarkers (Tumor Markers)IBA 10/2016
1	Cytidine DeaminaseIBA 04/2016
1	Genetic Markers (Genetic Marker)IBA 01/2016
1	GTP-Binding Proteins (G-Protein)IBA 01/2015
1	human ERBB2 proteinIBA 11/2014
1	Biological ProductsIBA 09/2013
1	GeranyltranstransferaseIBA 05/2013
1	Interleukin-18 (Interleukin 18)IBA 04/2013
1	Claudin-4IBA 01/2012
1	Bromodeoxyuridine (BrdU)IBA 01/2012
1	Small Interfering RNA (siRNA)IBA 04/2011
1	cytoplasmic antiproteinaseIBA 04/2011
1	Indicators and Reagents (Reagents)IBA 03/2011
1	Immunoglobulin G (IgG)IBA 03/2010
1	DNA (Deoxyribonucleic Acid)IBA 03/2010
1	Interleukin-10 (Interleukin 10)IBA 03/2010
1	CCAAT-Enhancer-Binding Protein-alphaIBA 09/2009
1	metabotropic glutamate receptor 6IBA 06/2009
1	AutoantigensIBA 02/2008
1	Transforming Growth Factor beta (TGF-beta)IBA 04/2007

Therapy/Procedure

11	Immunotherapy 01/2020 - 09/2002
4	Therapeutics 01/2017 - 04/2013
3	Drug Therapy (Chemotherapy) 06/2021 - 04/2013
2	Intravenous Infusions 01/2018 - 02/2010
2	Nephrectomy 08/2011 - 02/2010